Atogepant: Reducing Migraine Days in Episodic and Chronic Cases
- MigraineMind
- Nov 23, 2025
- 1 min read
Research Summary
A recent study published in CPT Pharmacometrics & Systems Pharmacology explored the exposure-response relationship of atogepant for preventing migraines. The research analyzed data from one phase 2b/3 and three phase 3 trials involving patients with episodic or chronic migraines. By using a modified normal distribution model, the study assessed how different atogepant concentrations influenced monthly migraine days. Results indicated that atogepant effectively reduces migraines with its maximum effect plateauing at concentrations similar to those achieved with a 10 mg daily dose. Importantly, all approved dosages reach levels sufficient to inhibit the calcitonin gene-peptide receptor by 90%. Treatment duration may need to be extended for patients with higher baseline migraine days or those unresponsive to previous treatments, but efficacy remains consistent regardless of prior preventive usage.
Study Details
👥 Research Team: Schlachter L et al.
📚 Published In: CPT Pharmacometrics Syst Pharmacol
📅 Publication Date: 2025 Nov 21
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.